Brokers Set Expectations for ASMB FY2029 Earnings

Assembly Biosciences, Inc. (NASDAQ:ASMB) – Research analysts at HC Wainwright issued their FY2029 earnings per share (EPS) estimates for shares of Assembly Biosciences in a note issued to investors on Monday, March 24th. HC Wainwright analyst E. Arce forecasts that the biopharmaceutical company will post earnings per share of ($12.58) for the year. HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for Assembly Biosciences’ current full-year earnings is ($6.87) per share.

Assembly Biosciences (NASDAQ:ASMB) last issued its quarterly earnings results on Thursday, March 20th. The biopharmaceutical company reported ($1.57) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.75) by $0.18. Assembly Biosciences had a negative net margin of 144.05% and a negative return on equity of 121.46%. The business had revenue of $7.36 million during the quarter, compared to analyst estimates of $7.05 million.

A number of other research firms also recently commented on ASMB. StockNews.com downgraded Assembly Biosciences from a “buy” rating to a “hold” rating in a research note on Monday. Guggenheim initiated coverage on Assembly Biosciences in a research report on Tuesday. They issued a “buy” rating and a $31.00 target price for the company.

Assembly Biosciences Stock Performance

ASMB opened at $11.42 on Tuesday. The company has a market capitalization of $72.59 million, a P/E ratio of -1.70 and a beta of 0.62. The company has a 50-day moving average of $12.77 and a 200-day moving average of $15.05. Assembly Biosciences has a 1-year low of $10.27 and a 1-year high of $19.93.

Insider Transactions at Assembly Biosciences

In related news, Director Michael Houghton bought 3,202 shares of the firm’s stock in a transaction on Monday, December 30th. The stock was bought at an average cost of $15.61 per share, for a total transaction of $49,983.22. Following the completion of the purchase, the director now directly owns 3,202 shares in the company, valued at approximately $49,983.22. The trade was a ∞ increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 5.10% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in ASMB. Gilead Sciences Inc. acquired a new position in shares of Assembly Biosciences during the fourth quarter valued at $34,865,000. Renaissance Technologies LLC increased its holdings in shares of Assembly Biosciences by 44.3% in the 4th quarter. Renaissance Technologies LLC now owns 94,711 shares of the biopharmaceutical company’s stock worth $1,495,000 after acquiring an additional 29,087 shares during the period. Peapod Lane Capital LLC bought a new stake in Assembly Biosciences in the 4th quarter valued at about $994,000. B Group Inc. acquired a new position in Assembly Biosciences during the 4th quarter valued at about $799,000. Finally, Monimus Capital Management LP bought a new position in Assembly Biosciences in the 4th quarter worth about $664,000. 19.92% of the stock is currently owned by institutional investors.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.